Provided by Tiger Trade Technology Pte. Ltd.

WAVE Life Sciences

4.90
-0.1400-2.78%
Post-market: 4.930.0300+0.61%19:43 EDT
Volume:3.81M
Turnover:18.68M
Market Cap:965.30M
PE:-4.55
High:5.07
Open:5.06
Low:4.84
Close:5.04
52wk High:21.73
52wk Low:4.84
Shares:197.00M
Float Shares:94.77M
Volume Ratio:1.33
T/O Rate:4.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0766
EPS(LYR):-1.2118
ROE:-67.42%
ROA:-33.60%
PB:2.13
PE(LYR):-4.04

Loading ...

Wave Life Sciences Down Over 49%, On Pace for Largest Percent Decrease Since December 2019 -- Data Talk

Dow Jones
·
Mar 27

Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink

TIPRANKS
·
Mar 26

Wave Life Sciences falls -57.6%

TIPRANKS
·
Mar 26

Wave Life Sciences Shares Down 56% as Obesity Drug Fails to Show Promise in Early-Stage Trial

THOMSON REUTERS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan

Reuters
·
Mar 26

Wave Life Sciences Says Obesity Drug Improved Body Composition in Study

Dow Jones
·
Mar 26

Wave Life Sciences Shares Plunge 54% Premarket After Co Reports Obesity Drug Early-Stage Trial Data

THOMSON REUTERS
·
Mar 26

Wave Life Sciences Ltd - to Initiate Phase 2a Inlight and New Wve-007 Trials as Incretin Add-on in 2026

THOMSON REUTERS
·
Mar 26

Wave Life Sciences Ltd: Additional Data From Inlight, Including Data From 600 Mg Phase 1 Sad Cohort, Are Expected in 2026

THOMSON REUTERS
·
Mar 26

Wave Life Sciences Ltd - Wve-007 Continues to Be Generally Safe and Well Tolerated

THOMSON REUTERS
·
Mar 26

Wave Life Sciences reports Phase 1 INLIGHT interim data; WVE-007 cuts visceral fat 14.3% at 6 months after a single 240 mg dose

Reuters
·
Mar 26

Wave Life Sciences Ltd : Mizuho Raises Target Price to $27 From $22

THOMSON REUTERS
·
Mar 25

Mizuho Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

TIPRANKS
·
Mar 25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pfizer (PFE) and Wave Life Sciences (WVE)

TIPRANKS
·
Mar 24

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)

TIPRANKS
·
Mar 16

Wave Life Sciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 11

Wave Life Sciences price target raised to $52 from $43 at Canaccord

TIPRANKS
·
Mar 10

Wave Life Sciences Ltd : Canaccord Genuity Raises Target Price to $52 From $43

THOMSON REUTERS
·
Mar 10

Wave Life Sciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 06

Wedbush Adjusts Wave Life Sciences PT to $35 From $33, Maintains Outperform Rating

MT Newswires Live
·
Mar 06